# of Displayed Technologies: 3 / 3


Categories

Adoptive Transfer of Engineered Macrophages
TS-045881 — The Need Cell therapies have received recent approvals for immunomodulatory indications. Immuno-activating chimeric antigen receptor (CAR)–T cells have been developed for cancers, whereas immunosuppressive mesenchymal stromal cells (MSCs) have been approved for inflammatory bowel disease and …
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Hou, Xucheng; Zhang, Xinfu
  • Licensing Officer: Flammang, Ann Marie

mRNA sequence engineering and uses thereof
TS-045448 — Maximized mRNA lifespan and translation for mRNA-based therapy applications.
Many diseases emerge from irregularities that occur during protein synthesis. While limited therapies exist to deliver mature proteins to compensate for these errors, protein therapy by direct protein delivery has limited efficiency. This is due to difficulty in controlling the volume of delivered…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Zeng, Chunxi
  • Licensing Officer: Flammang, Ann Marie

Improving immunotherapy with mRNA delivery
TS-045426 — The central mission of cancer immunotherapy treatments is to aid the immune system in detecting and degrading cancer cells. For twenty years, the use of monoclonal antibodies (mAbs) as anti-tumor drugs has been successful in managing cancer disease and increasing patient lifespan. These treatments…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Li, Wenqing; Zhang, Chengxiang
  • Licensing Officer: Flammang, Ann Marie

Loading icon